Implications of discontinuation of doxazosin arm of ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

Lancet. 2000 Mar 11;355(9207):863-4. doi: 10.1016/s0140-6736(00)00092-1.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adverse Drug Reaction Reporting Systems
  • Anticholesteremic Agents / adverse effects*
  • Anticholesteremic Agents / therapeutic use
  • Antihypertensive Agents / adverse effects*
  • Antihypertensive Agents / therapeutic use
  • Chlorthalidone / adverse effects
  • Chlorthalidone / therapeutic use
  • Doxazosin / adverse effects*
  • Doxazosin / therapeutic use
  • Heart Failure / chemically induced*
  • Humans
  • Myocardial Infarction / prevention & control*
  • United States

Substances

  • Anticholesteremic Agents
  • Antihypertensive Agents
  • Doxazosin
  • Chlorthalidone